Standard BioTools Inc. reported a 5% revenue increase to $21.1 million in Q1 2026, driven by strong consumables sales despite a 33% drop in instrument revenue. The company reduced its operating loss by 54% and improved adjusted EBITDA loss by 78%, signaling progress toward profitability in 2026. With $524 million in cash and investments, Standard BioTools plans to pursue growth opportunities following the sale of SomaLogic. The company maintains its 2026 revenue forecast of $80-$85 million, focusing on cost savings and strategic capital deployment.
The global pharmaceutical surfactants market, valued at $4.5 billion in 2025, is projected to grow to $6.93 billion by 2035 at a CAGR of 4.42%. Growth is fueled by increasing use in drug formulation to enhance solubility, stability, and bioavailabili...
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Agility Robotics, backed by Humanoid Global, is set to go public in 2026 via a merger with Churchill Capital Corp XI, valuing the company at $2.5 billion and raising over $620 million. The funds will support scaling production of its Digit v5 humanoi...
The London Company Mid Cap portfolio returned 9.7% (9.5% net) in the second quarter, underperforming the Russell Midcap Index which rose 13.8%. The market gains were driven mainly by momentum and high-beta stocks, with the top beta quintile returning...
The US Senate Commerce Committee advanced legislation that would ban the sale of connected vehicles in the US by companies with more than 15% Chinese ownership, potentially affecting Mercedes-Benz, which has nearly 20% Chinese investor stakes. The bi...
